Louisiana State Employees Retirement System Invests $1.12 Million in Labcorp Holdings Inc. $LH

Key Points

• Louisiana State Employees Retirement System bought a new stake in Labcorp during Q1, acquiring 4,200 shares valued at about $1.12 million.
• Labcorp’s recent earnings beat expectations, reporting $4.25 EPS on $3.54 billion in revenue, and the company raised its FY2026 guidance to 17.7–18.35 EPS.
• Analysts remain generally constructive, with a Moderate Buy consensus and an average price target of $308, while the stock was recently trading near $286.69.

Louisiana State Employees Retirement System acquired a new stake in Labcorp Holdings Inc. (NYSE:LH - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,200 shares of the medical research company's stock, valued at approximately $1,121,000.

A number of other institutional investors have also made changes to their positions in the business. JPL Wealth Management LLC acquired a new position in Labcorp during the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp in the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new stake in Labcorp during the 4th quarter worth about $27,000. Eagle Bay Advisors LLC bought a new stake in Labcorp during the 4th quarter worth about $29,000. Finally, DV Equities LLC acquired a new position in shares of Labcorp during the 4th quarter worth about $29,000. Institutional investors own 95.94% of the company's stock.

Analysts Set New Price Targets

LH has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Labcorp in a research report on Friday, May 8th. Robert W. Baird set a $334.00 price target on Labcorp in a research report on Friday, May 1st. Wall Street Zen downgraded Labcorp from a "buy" rating to a "hold" rating in a research note on Saturday, June 13th. Finally, Evercore reaffirmed an "outperform" rating and set a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Labcorp has a consensus rating of "Moderate Buy" and an average price target of $308.00.

Labcorp Stock Down 0.1%

LH stock opened at $286.69 on Friday. Labcorp Holdings Inc. has a 1-year low of $241.81 and a 1-year high of $293.72. The business's 50 day simple moving average is $262.24 and its 200 day simple moving average is $266.25. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $23.51 billion, a PE ratio of 25.39, a PEG ratio of 2.01 and a beta of 0.89.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter last year, the firm posted $3.84 EPS. The company's quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, research analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Friday, May 29th. Labcorp's dividend payout ratio (DPR) is currently 25.51%.

Insider Transactions at Labcorp

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the transaction, the executive vice president directly owned 3,813 shares of the company's stock, valued at $1,006,212.57. This represents a 16.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares of the company's stock, valued at $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company's stock.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.